The blood-brain tumor barrier (BTB) significantly impedes delivery of most hydrophilic molecules to brain tumors. Several promising strategies, however, have been developed to overcome this problem.
Methods
We discuss several drug delivery methods to brain tumor, including intracerebroventricular, convectionenhanced delivery, BBB/BTB disruption, and BTB permeability modulation, which was developed in our laboratory.
Results
Using immunolocalization, immunoblotting, and potentiometric studies, we found that brain tumor capillary endothelial cells overexpress certain unique protein markers that are absent or barely detectable in normal capillary endothelial cells. We biochemically modulated these markers to sustain and enhance drug delivery, including molecules of varying sizes, selectively to tumors in rat syngeneic and xenograft brain tumor models. We also demonstrated that the cellular mechanism for vasomodulator-mediated BTB permeability increase is due to accelerated formation of pinocytotic vesicles that transport therapeutic molecules across the BTB.
Conclusions
Other methods to deliver drugs across the BTB are effective but have severe drawbacks. Our strategy targets BTB-specific proteins to increase antineoplastic drug delivery selectively to brain tumors with few or no side effects, thus increasing the possibility of improving brain tumor treatment.
References
1.
PardridgeW.M.Blood-brain barrier genomics. In: PardridgeW.M., ed. Brain Drug Targeting: The Future of Brain Drug Development.Cambridge; New York: Cambridge University Press; 2001.
2.
CloughesyT.F., BlackK.L.Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol.1995; 26: 125–132.
3.
FishmanR.A., ChristyN.P.Fate of adrenal cortical steroids following intrathecal injections. Neurology.1965; 15: 1–6.
4.
FungL.K., ShinM., TylerB.Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res.1996; 13: 671–682.
5.
van den BentM.J., TaphoornM.J., BrandesA.A.Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol.2003; 21: 2525–2528.
6.
AsotraK., NingarajN.S., BlackK.L.Measurement of blood-brain and blood-tumor barrier permeabilities with [14C]-labeled tracers. In: NagS., ed. The Blood Brain Barrier: Biology and Research Protocols.Totowa, NJ: Humana Press; 2003.
7.
BakerS.D., WirthM., StatkevichP.Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res.1999; 5: 309–317.
8.
SawchukR.J., YangZ.Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev.1999; 39: 5–31.
9.
KunwarS.Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl.2003; 88: 105–111.
10.
LiC., HallW.A., JinN.Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng.2002; 15: 419–427.
11.
IkedaM., NagashimaT., BhattacharjeeA.K.Quantitative analysis of hyperosmotic and hypothermic blood-brain barrier opening. Acta Neurochir Suppl.2003; 86: 559–563.
12.
MarchiN., RasmussenP., KapuralM.Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci.2003; 21: 109–121.
BhattacharjeeA.K., NagashimaT., KondohT.Quantification of early blood-brain barrier disruption by in situ brain perfusion technique. Brain Res Brain Res Protoc.2001; 8: 126–131.
15.
KannerA.A., MarchiN., FazioV.Serum S100 beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer.2003; 97: 2806–2813.
16.
SiegalT., RubinsteinR., BoksteinF.In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg.2000; 92: 599–605.
17.
BlackK.L., HoffJ.T., McGillicuddyJ.E.Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans. Ann Neurol.1986; 19: 592–595.
BlackK.L., CloughesyT., HuangS.C.Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg.1997; 86: 603–609.
20.
HashizumeK., BlackK.L.Increased endothelial vesicular transport correlates with increased blood-tumor barrier permeability induced by bradykinin and leukotriene C4. J Neuropathol Exp Neurol.2002; 61: 725–735.
21.
SugitaM., BlackK.L.Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors. Cancer Res.1998; 58: 914–920.
MatsukadoK., SugitaM., BlackK.L.Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas. Brain Res.1998; 792: 10–15.
24.
LiuY., HashizumeK., ChenZ.Correlation between bradykinin-induced blood-tumor barrier permeability and B2 receptor expression in experimental brain tumors. Neurol Res.2001; 23: 379–387.
25.
PardridgeW.M., BoadoR.J., BlackK.L.Blood-brain barrier and new approaches to brain drug delivery. West J Med.1992; 156: 281–286.
26.
NingarajN.S., RaoM., HashizumeK.Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther.2002; 301: 838–851.
27.
NingarajN.S., RaoM., BlackK.L.Calcium-dependent potassium channels as a target protein in the modulation of blood-brain tumor barrier. Drug News Perspect.2003; 16: 291–298.
28.
NingarajN.S., RaoM.K., BlackK.L.Adenosine 5′-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res.2003; 63: 8899–8911.
29.
GregorA., LindM., NewmanH.Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma: RMP-7 European Study Group. J Neurooncol.1999; 44: 137–145.
30.
FordJ., OsbornC., BartonT.A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer.1998; 34: 1807–1811.
31.
PradosM.D., ScholdS.C.Jr, FineH.A.A randomized, double blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neurooncol.2003; 5: 96–103.
32.
HallJ.M.Bradykinin receptors. Gen Pharmacol.1997; 28: 1–6.
33.
PizardA., BlaukatA., Muller-EsterlW.Bradykinin-induced internalization of the human B2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail. J Biol Chem.1999; 274: 12738–12747.
34.
NakanoS., MatsukadoK., BlackK.L.Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res.1996; 56: 4027–4031.
35.
KhanF., PearsonR.J., NewtonD.J.Chemical synthesis and microvascular effects of new nitric oxide donors in humans. Clin Sci (Lond).2003; 105: 577–584.
36.
JooF., TemesvariP., DuxE.Regulation of the macromolecular transport in the brain microvessels: the role of cyclic GMP. Brain Res.1983; 278: 165–174.
37.
KuboM., NakayaY., MatsuokaS.Atrial natriuretic factor and isosorbide dinitrate modulate the gating of ATP-sensitive K+ channels in cultured vascular smooth muscle cells. Circ Res.1994; 74: 471–476.
38.
BraydenJ.E.Functional roles of KATP channels in vascular smooth muscle. Clin Exp Pharmacol Physiol.2002; 29: 312–316.
39.
ProescholdtM.A., HeissJ.D., WalbridgeS.Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol.1999; 58: 613–627.
